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AbstrAct
Introduction Peripheral arterial tonometry (PAT) is an 
operator- independent and non- invasive measurement 
method to assess microvascular endothelial function 
in the fingertips. PAT- derived measures of endothelial 
function were associated with type 2 diabetes in cross- 
sectional studies. However, longitudinal studies are 
lacking. The study aims to investigate the association of 
two PAT- derived endothelial function parameters reactive 
hyperemia index (RHI) and mean baseline amplitude (MBA) 
with follow- up glucose and insulin parameters and the 
development of (pre)diabetes and type 2 diabetes.
Research design and methods The study included 
673 participants initially without diabetes (328 men and 
345 women) aged 52–71 years from the prospective 
population- based Cooperative Health Research in the 
Region of Augsburg F4/FF4 cohort study conducted in 
Southern Germany (baseline examination F4: 2006–2008; 
follow- up FF4: 2013–2014). An oral glucose tolerance test 
was performed at baseline and follow- up to define type 
2 diabetes, prediabetes, fasting glucose, fasting insulin, 
2- hour glucose, homeostasis model assessment of insulin 
resistance (HOMA- IR), homeostasis model assessment of 
beta- cell function and hemoglobin A1c.
Results In multivariable adjusted logistic/linear regression 
models, a 1 SD increase in baseline RHI was inversely 
associated with incident type 2 diabetes (OR 0.69 (95% 
CI 0.48 to 0.97)) as well as with fasting insulin (β −0.069 
(95% CI −0.131 to −0.007)) and HOMA- IR (β −0.072 (95% 
CI −0.133 to −0.010)) at follow- up in participants with 
initial normoglycemia. A 1 SD increase in baseline MBA 
was positively associated with incident (pre)diabetes (OR 
1.62 (95% CI 1.25 to 2.11)) and fasting glucose (β 0.096 
(95% CI 0.047 to 0.146)) at follow- up in participants with 
initial normoglycemia.
Conclusions Microvascular endothelial dysfunction seems 
to be involved in the development of early derangements 
in glucose metabolism and insulin resistance and could 
thereby trigger the development of prediabetes and type 2 
diabetes.
InTRoduCTIon
The endothelium plays a substantial role in 
regulating circulatory blood flow, fibrinolysis 
and coagulation within the vessels.1–3 Endo-
thelial dysfunction is defined as impaired 
homeostasis between vasoconstriction and 
vasodilation of the vessels leading to decreased 
dilation of the vessel, inflammation and clot 
formation.4 5 As endothelial dysfunction is the 
first stage of atherosclerosis,4 6 it represents 
an early target to prevent cardiovascular risk 
factors in patients with insulin resistance or 
type 2 diabetes.7 Using measures of endo-
thelial function, arterial abnormalities can 
be detected even before structural changes 
significance of this study
What is already known about this subject?
 ► Reactive hyperemia index (RHI) and pulse amplitude, 
parameters of microvascular endothelial dysfunc-
tion, were associated with type 2 diabetes and relat-
ed parameters in previous cross- sectional studies.
What are the new findings?
 ► Baseline measurement of RHI was inversely as-
sociated with the development of incident type 2 
diabetes.
 ► The association was attenuated after adjusting for 
fasting insulin and homeostasis model assessment 
of insulin resistance, suggesting a potential mediat-
ing role of insulin resistance.
 ► Baseline measurement of pulse amplitude (MBA) 
was positively associated with incident (pre)diabetes 
and fasting glucose at follow- up in participants with 
initial normoglycemia.
 ► RHI and MBA seem to measure different microvas-
cular endothelial mechanisms in relation to the de-
velopment of diabetes.
How might these results change the focus of 
research or clinical practice?
 ► Besides measurements of macrovascular, also mea-
surements of microvascular endothelial dysfunction 
appear to be involved in the development of incident 
type 2 diabetes and (pre)diabetes.
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of the vessel wall and clinical symptoms develop. More-
over, improvements in endothelial function are linked 
to reduced cardiovascular morbidity and mortality.8 This 
provides a great opportunity in terms of prevention, 
especially because endothelial dysfunction is reversible 
in contrast to manifest cardiovascular diseases.6 8
To assess endothelial function, we used peripheral 
arterial tonometry (PAT), a non- invasive method, which 
measures the pulse volume, that is, blood flow within the 
index fingers before and after a 5 min cuff occlusion of 
the brachial artery. The resulting variables include the 
mean baseline amplitude (MBA) reflecting the baseline 
change in blood flow during pulse waves, and the reac-
tive hyperemia index (RHI) representing the reactivity 
of the endothelium to the occlusion. MBA and RHI are 
inversely correlated.9 A lower MBA and a higher RHI are 
assumed to reflect a better microvascular endothelial 
function. A more frequently used alternative technique 
for measurement of the stimulated endothelial reactivity 
is the flow- mediated dilation (FMD). Both techniques 
are based on the same physiological measurements in 
terms of initiating ischemia in the arm to trigger reactive 
vasodilation.10 The substantial difference between these 
two methods constitutes that the PAT method measures 
the microvascular function, whereas FMD measures the 
function of large arteries.11 Although both measure the 
endothelial function, the methods should not be used 
interchangeably because, as they measure endothelial 
function parameters in different vascular beds, PAT and 
FMD relate to different cardiovascular risk factors. One 
of the reasons for using the PAT method within this 
project is the advantage of operator independence in 
contrast to FMD.6 12 13 Therefore, PAT is easier to imple-
ment within large population- based studies. A further 
advantage of the PAT is that the contralateral arm serves 
as an internal control to increase the validity of the RHI 
measurements.10
Endothelial dysfunction is contemplated to be an 
important factor in the pathogenesis of type 2 diabetes, 
possibly linked through hyperglycemia,7 insulin resis-
tance,13 beta- cell dysfunction14 and mitochondrial DNA 
damage,15 which increase oxidative stress, inflammation 
and luminal obstruction of the large arteries. However, 
previous cross- sectional studies yielded contradictory 
results in linking PAT- measured microvascular endothe-
lial dysfunction to type 2 diabetes as well as related glucose 
and insulin parameters.9 11 16–19 The prospective Moni-
toring of Trends and Determinants in Cardiovascular 
Disease/Cooperative Health Research in the Region of 
Augsburg (KORA) S1- S3 case- cohort study revealed an 
association between endothelial dysfunction and risk of 
type 2 diabetes using the biomarkers soluble E- selectin 
and soluble intracellular adhesion molecule-1, which 
are known to be associated with endothelial dysfunc-
tion.20 Other prospective studies, using biomarkers of 
endothelial dysfunction, support these results,21 22 and 
endothelial dysfunction ranked among the top five most 
important pathways in a recent biomarker- based analysis 
of the relevance of 19 etiological pathways.23 Longitu-
dinal studies, which use FMD or more direct measures 
of endothelial function, such as acetylcholine- stimulated 
forearm blood flow, are scarce.24 25 A prospective cohort 
study investigating postmenopausal women demonstrated 
a significant increase in the relative risk of type 2 diabetes 
with decreased FMD.24 In a further prospective study with 
hypertensive patients, the maximal vasodilatory response 
to intra- arterial infusion of acetylcholine was inversely 
associated with incident type 2 diabetes independent of 
traditional and emerging cardiovascular risk factors.25 We 
are not aware of any study, which investigated the asso-
ciation between microvascular endothelial function and 
incident type 2 diabetes prospectively in a population- 
based sample using the PAT method. Therefore, the 
present study aimed to examine the longitudinal associa-
tion of the two endothelial function parameters RHI and 
MBA with the development of type 2 diabetes and (pre)
diabetes, as well as parameters of glucose metabolism and 
insulin resistance over a follow- up period of 7 years.
MeTHods
study population
Data were derived from the population- based KORA 
F4/FF4 study, conducted in Southern Germany. For the 
baseline study KORA S4 (1999–2001), 6640 persons were 
selected out of the target population of all German citi-
zens, aged 25–74 years living in the region of Augsburg, 
based on population registries of the city of Augsburg 
and two adjacent counties. Out of these, 4261 individuals 
participated in the S4 baseline examinations. The KORA 
F4 study (2006–2008) is the first follow- up of the KORA 
S4 baseline study and included 3080 participants (1486 
men and 1594 women) aged 32–81 years. The second 
follow- up study FF4 (2013/14) included 2161 partici-
pants.26 For the present analysis, we used data from F4 as 
the baseline (exposure, covariates) and from FF4 as the 
follow- up (outcome). PAT measurements at F4 were only 
performed in the subgroup of participants aged 52–71 
years, without clinically diagnosed diabetes or any contra-
indications (eg, hemophilia and thrombosis) (figure 1). 
All participants lost to follow- up were excluded from all 
analysis. All missing data were excluded for the respective 
analysis. Details concerning participant exclusions are 
illustrated in figure 1.
exposure
All participants received physical and medical examina-
tions at the F4 and FF4 surveys by trained medical staff.
Endothelial function was assessed using PAT with the 
Endo- PAT2000 device produced by the company Itamar 
Medical (Caesarea, Israel). The system is computer- 
based, non- invasive and it calculates the test results 
automatically, which makes the measurement operator- 
independent. The Endo- PAT2000 uses a finger plethys-
mograph consisting of sensors, which measure the 
dynamics and extent of tone changes at the tips of both 
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Figure 1 Flow chart of study participants and exclusions. *Including 111 participants with prediabetes at FF4 and 19 
participants with type 2 diabetes at FF4. HbA1c, hemoglobin A1c; HOMA- beta, homeostasis model assessment of beta- cell 
function; HOMA- IR, homeostasis model assessment of insulin resistance; OGTT, oral glucose tolerance test; T2D, type 2 
diabetes.
index fingers through the amplitude of the pulse waves. 
A pulse wave amplitude is the ‘difference between the 
highest and lowest point of a pulse wave’.27 The pulse 
wave amplitude was measured 5 min before, during and 
5 min after a 5 min occlusion of the brachial artery of the 
non- dominant upper arm. The values for the premeasure-
ments and postmeasurements were calculated separately 
out of the mean of the pulse wave amplitudes during the 
5 min preocclusion and postocclusion. The non- occluded 
arm served as the control. The RHI was calculated as 
((pulse amplitude of the occluded arm postocclusion/
pulse amplitude of the occluded arm preocclusion)/
(pulse amplitude of the control arm postocclusion/pulse 
amplitude of the control arm preocclusion))×baseline 
correction. The MBA was calculated as the mean of the 
pulse wave amplitudes of the occluded and control arms 
preocclusion. The PAT measurements were performed 
after the participants had received the oral glucose toler-
ance test (OGTT) and eaten a standardized breakfast. A 
detailed description of the PAT measurements is given in 
the online supplementary file.
outcomes
Known diabetes was defined based on the participant’s 
self- report and subsequent validation by the respon-
sible physician or medical chart review, or self- reported 
current use of glucose- lowering medication. All partic-
ipants without known diabetes received the OGTT.28 
The OGTT was performed after an overnight fast of at 
least 8 hours. During the fast only drinking water was 
allowed.29 The participants received 75 g carbohydrates 
as a 300 mL sugar solution. They ingested the solution 
copyright.
 on O














are: first published as 10.1136/bm




4 BMJ Open Diab Res Care 2020;8:e001321. doi:10.1136/bmjdrc-2020-001321
Epidemiology/Health Services Research
in the morning, not later than 11:00 a.m. and drank the 
solution within 5 min. The participants received a blood 
withdrawal before and 2 hours after the carbohydrate 
intake. The blood samples were centrifuged and kept 
cool at 4°C until analysis in the study center, which was 
maximally 6 hours after the samples were taken.29 The 
categorical parameters newly diagnosed type 2 diabetes, 
prediabetes (including isolated impaired fasting 
glycemia (i- IFG), isolated impaired glucose tolerance 
(i- IGT) and the combination of IFG/IGT) and normal 
glucose tolerance (NGT) were defined according to 
1999 WHO diagnostic criteria30 (detailed description 
in the online supplementary file). The binary outcome 
incident type 2 diabetes included newly diagnosed 
OGTT- based diabetes and known type 2 diabetes (diag-
nosed between F4 and FF4) identified at FF4. The corre-
sponding participants without incident type 2 diabetes 
comprised participants with NGT, i- IFG, i- IGT and IFG/
IGT at FF4 follow- up. The outcome incident (pre)
diabetes included newly diagnosed OGTT- based type 2 
diabetes, known type 2 diabetes, i- IFG, i- IGT and IFG/
IGT. Participants with NGT at F4 and FF4 represented 
the reference group.
The continuous parameters fasting glucose, fasting 
insulin and hemoglobin A1c (HbA1c) were assessed in 
fasting blood samples obtained before the OGTT. HbA1c 
was measured using ion- exchange high- performance 
liquid chromatography in whole blood using the Adams 
HA 8160 Hemoglobin Analysis System (Arkray, distrib-
uted by A. Menarini Diagnostics, Florence, Italy) in 
KORA F4 and the Variant II Turbo HbA1c Kit-2.0 (Bio- 
Rad Laboratories, Hercules, USA) in KORA FF4. In 
KORA F4, glucose was measured using the hexokinase 
method (GLU Flex, Dade Behring, Deerfield, Illinois, 
USA). In KORA FF4, glucose was measured by an enzy-
matic, colorimetric method using the GLU assay on a 
Dimension Vista 1500 instrument (Siemens Healthcare 
Diagnostics, Newark, USA) or GLUC3 assay, on a Cobas 
c702 instrument (Roche). In KORA F4, insulin was deter-
mined in thawed serum by an electrochemiluminescence 
immunoassay on a Cobas e602 instrument (Roche Diag-
nostics, Mannheim, Germany). In KORA FF4, insulin 
was measured with solid- phase enzyme- labeled chemi-
luminescent immunometric assay on an Immulite 2000 
systems analyzer (Siemens) or with electrochemilumi-
nescence immunoassay on a Cobas e602. The instru-
ments that were used to determine insulin and glucose 
changed in KORA FF4 from Siemens to Roche halfway 
during the study. No calibration was needed for glucose. 
The Siemens insulin data were calibrated using a formula 
developed from 194 FF4 samples, which were measured 
with both instruments.28
Homeostasis model assessment of insulin resistance 
(HOMA- IR) was calculated using the formula: (fasting 
insulin (mU/L)×fasting glucose (mmol/L))/22.5 
and homeostasis model assessment of beta- cell func-
tion (HOMA- beta) using the formula: (fasting insulin 
(mU/L)×20)/(fasting glucose (mmol/l)–3.5).
Covariates
Trained medical staff assessed information on sociodemo-
graphic data (eg, age, sex and education), lifestyle (eg, 
smoking, physical activity and alcohol intake), medica-
tion use, disease history and parental history of diabetes 
during a standardized face- to- face interview in the F4 
survey. Detailed information describing the measure-
ments and variable classifications of the covariates can be 
found in the online supplementary file.
statistical analysis
All statistical analyses were performed using R, V.3.4.4 
(R Core Team. R: a language and environment for 
statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria, 2018). RHI and MBA were 
standardized by dividing the values by their respec-
tive SD. The outcomes fasting insulin, HOMA- IR and 
HOMA- beta, as well as the covariates triglycerides and 
high- sensitivity C reactive protein (hsCRP), were trans-
formed using natural logarithmic transformation. All 
continuous outcome variables (fasting glucose, fasting 
insulin, 2- hour glucose, HOMA- IR, HOMA- beta and 
HbA1c) were z- standardized by subtracting the mean 
from the values and dividing the difference by the 
respective SD. The associations of RHI and MBA with 
incident (pre)diabetes and incident type 2 diabetes 
were calculated using multivariable logistic regression 
models. For the associations of RHI and MBA with the 
continuous glucose and insulin parameters, we used 
multivariable linear regression models. Interactions 
between RHI or MBA and glucose tolerance status 
at baseline were assessed in the full study sample by 
inclusion of interaction terms in the linear regression 
models. Due to observed interactions in some models, 
all analyses regarding the continuous outcomes were 
stratified according to glucose tolerance status at base-
line (ie, NGT and prediabetes). All regressions were 
adjusted using possible confounders based on liter-
ature research in two consecutive models. Model 1 
included sex, age and the baseline value (at F4) of the 
continuous outcomes fasting glucose, fasting insulin, 
2- hour glucose, HOMA- IR, HOMA- beta and HbA1c 
(only for linear regressions). Model 2 comprised waist 
circumference, height, triglycerides, total cholesterol/
high- density lipoprotein (all continuous), actual hyper-
tension (two categories), smoking status (three catego-
ries), alcohol intake (three categories), physical activity 
(four categories), low education (two categories), 
hsCRP (continuous) and parental history of diabetes 
(three categories). The logistic regression model 
assessing the association of RHI with incident type 2 
diabetes (model 2) was further adjusted for baseline 
HOMA- IR and fasting insulin (in two separate models) 
to investigate their role as potential mediators of the 
association. The logistic regression model assessing 
the association of MBA with (pre)diabetes (model 2) 
was further adjusted for baseline fasting glucose. Test 
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results with two- sided p value <0.05 were considered 
statistically significant.
ResulTs
Table 1 summarizes the characteristics of the participants 
of the whole study population (n=673) and stratified by 
the two main outcomes of our study, that is, incident type 
2 diabetes versus no incident type 2 diabetes and incident 
(pre)diabetes versus NGT. RHI was lower and MBA higher 
in participants with incident type 2 diabetes compared 
with participants without incident type 2 diabetes as well 
as in participants with incident (pre)diabetes compared 
with participants with NGT. In partial correlation anal-
ysis, MBA and RHI were inversely correlated after adjust-
ment for age and sex (estimate: −0.412, p=7.87e-29).
Baseline RHI was inversely associated with incident 
type 2 diabetes at follow- up in model 2 (OR 0.69 (95% 
CI 0.48 to 0.97)) (table 2). The association was attenu-
ated after further adjustment for baseline HOMA- IR (OR 
0.73 (95% CI 0.49 to 1.03)) or insulin (OR 0.71 (95% 
CI 0.48 to 1.01)). In participants with NGT at baseline, 
baseline RHI was significantly inversely associated with 
fasting insulin (β −0.069 (95% CI −0.131 to −0.007)) and 
with HOMA- IR (β −0.072 (95% CI −0.133 to −0.010)) in 
model 2. For fasting glucose, 2- hour glucose, HOMA- beta 
and HbA1c the associations were not statistically signif-
icant, but effect estimates were aligned into the same 
direction (figure 2, online supplementary table S1). 
Among participants with prediabetes at baseline, we did 
not observe any significant associations between RHI and 
the continuous outcomes (online supplementary figure 
S1, table S2).
Baseline MBA was positively associated with incident 
(pre)diabetes (OR 1.62 (95% CI 1.25 to 2.11)) in model 
2 (table 2). After adjustment for baseline glucose, the 
effect estimate decreased slightly (OR 1.56 (95% CI 1.20 
to 2.05). In participants with NGT, MBA was also signifi-
cantly positively associated with fasting glucose, 2- hour 
glucose, HOMA- IR, and HbA1c in model 1. However, 
only results for fasting glucose remained statistically 
significant after further adjustment (model 2) (β 0.096 
(95% CI 0.047 to 0.146) (figure 2, online supplemen-
tary table S1). Among participants with prediabetes at 
baseline, we did not observe any significant associations 
between MBA and the continuous outcomes (online 
supplementary figure S1, table S2).
dIsCussIon
The present project showed that RHI was inversely asso-
ciated with incident type 2 diabetes as well as HOMA- IR 
and fasting insulin levels at follow- up in participants who 
were normoglycemic at baseline. On the other hand, 
MBA was positively associated with incident (pre)diabetes 
and fasting glucose levels at follow- up in participants with 
initial normoglycemia. To the best of our knowledge, this 
is the first population- based study that assessed longitu-
dinal associations of RHI and MBA with the development 
of prediabetes as well as type 2 diabetes and related traits. 
Our longitudinal data extend previous cross- sectional 
study results and suggest that microvascular endothe-
lial dysfunction might play a role in the development of 
prediabetes and type 2 diabetes.
A few preceding cross- sectional studies observed signif-
icant associations of PAT- derived measures of endothe-
lial function with type 2 diabetes.9 11 16–19 In interpreting 
the results of these studies, one has to take into account 
that some of them used somewhat divergent parameters 
of endothelial function including the F- RHI, a natural 
logarithmic transformation of the RHI without base-
line correction. Also with regard to the MBA, slightly 
different parameters have been used. For instance, some 
studies used the baseline pulse amplitude, representing 
the MBA of only the occluded arm (specified only in 
some studies). However, as the F- RHI and the RHI as well 
as the baseline pulse amplitude and the MBA are highly 
correlated with each other, their results are assumed to 
be comparable. Generally in line with our longitudinal 
study, two cross- sectional studies displayed that baseline 
pulse amplitude was positively and F- RHI was inversely 
associated with diabetes in age- adjusted and sex- adjusted 
models.9 11 Another study investigating a Brazilian popu-
lation found a positive association of baseline pulse 
amplitude with diabetes in age- adjusted and sex- adjusted 
models.16 While in the same study the inverse association 
of F- RHI with diabetes was not statistically significant 
in the age- adjusted and sex- adjusted model, F- RHI was 
significantly inversely associated with fasting glucose, 
further supporting a link between endothelial function 
and glucose metabolism.16 In contrast, another study 
found no association of diabetes with F- RHI, RHI and 
baseline pulse amplitude in age- adjusted and sex- adjusted 
models.18 However, this study was based on a Japanese 
population and the participants were at high risk for 
cardiovascular events. Another study displayed that self- 
reported history of diabetes was not associated with RHI 
and F- RHI after adjustment for age, sex and further 
nine diabetes- related traits.19 Furthermore, prior studies 
investigated the cross- sectional association of continuous 
insulin and glucose parameters with endothelial func-
tion parameters.9 11 16–19 Baseline pulse amplitude was 
positively and F- RHI was inversely associated with fasting 
glucose in age- adjusted and sex- adjusted models in two 
cross- sectional studies.9 11 Two of the three studies that 
found no association of endothelial function parameters 
with diabetes, did also not find an association with the 
glucose parameters.18 19 Causes of the conflicting results 
of the association of diabetes and related parameters 
with endothelial function parameters could be different 
ethnicities of the participants as well as different sample 
sizes and number of participants with diabetes.
The endothelial function parameter RHI is contem-
plated to reflect the reactive dilation of the endothelium 
through vasodilators such as nitric oxide (NO). This was 
for instance displayed in a study using healthy humans, 
which showed that acute inhibition of NO synthase 
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Variables measured at baseline (F4)
  Age (years)† 60.6±5.6 60.3±5.5 63.1±5.3 <0.001 59.9±5.6 61.0±5.2 0.030
  Sex male, n (%) 328 (48.7) 282 (48.1) 41 (60.3) 0.076 154 (41.4) 78 (60.0) <0.001
  Height (cm)† 168.1±8.9 168.2±8.9 168.3±8.8 0.778 167.8±8.9 168.3±8.4 0.339
  Waist circumference (cm)† 94.2±13.3 93.5±13.3 102.1±11.2 <0.001 90.6±11.7 97.7±11.1 <0.001
  Triglycerides (mmol/L)‡ 1.26 (1.02) 1.23 (1.05) 1.63 (1.15) <0.001 1.13 (1.07) 1.35 (1.12) 0.001
  Total cholesterol/HDL† 4.15±1.1 4.11±1.12 4.70±1.17 <0.001 3.92±1.08 4.44±1.14 <0.001
  Hypertension, n (%) 266 (39.5) 221 (37.7) 40 (58.8) 0.001 114 (30.6) 63 (48.5) <0.001
  Smoking status, n (%)       0.103     0.536
   Never 295 (43.8) 248 (42.3) 38 (55.9) 156 (41.9) 60 (46.2)
   Former 287 (42.7) 258 (44) 23 (33.8) 164 (44.1) 50 (38.5)
   Current 91 (13.5) 80 (13.7) 7 (10.3) 52 (14.0) 20 (15.4)
  Alcohol intake, n (%)       0.976     0.798
   0 g/day 185 (27.5) 159 (27.1) 19 (27.9) 103 (27.7) 40 (30.8)
   Men 0.1–39.9 g/day
   Women 0.1–19.9 g/day
344 (51.1) 300 (51.2) 35 (51.5) 192 (51.6) 64 (49.2)
   Men ≥40 g/day
   Women ≥20 g/day
144 (21.4) 127 (21.7) 14 (20.6) 77 (20.7) 26 (20.0)
  Physical activity, n (%)       0.114     0.201
   No activity 170 (25.3) 143 (24.4) 21 (30.9) 83 (22.3) 32 (24.6)
   Low activity 78 (11.6) 65 (11.1) 10 (14.7) 35 (9.4) 19 (14.6)
   Moderate activity 234 (34.8) 203 (34.6) 26 (38.2) 133 (35.8) 47 (36.2)
   High activity 191 (28.4) 175 (29.9) 11 (16.2) 121 (32.5) 32 (24.6)
  Education ≤10 years, n (%) 319 (47.4) 270 (46.1) 41 (60.3) 0.036 166 (44.6) 67 (51.5) 0.208
  High- sensitivity C reactive 
protein (mg/L)‡
1.20 (1.04) 1.16 (1.10) 1.77 (1.32) 0.002 0.99 (1.12) 1.53 (1.23) <0.001
  Parental history of diabetes, n (%)   0.104     0.003
   No parent 368 (54.7) 329 (56.1) 28 (41.2) 228 (61.3) 56 (43.1)
   Unknown 134 (19.9) 113 (19.3) 16 (23.5) 60 (16.1) 36 (27.7)
   One parent 155 (23.0) 131 (22.4) 21 (30.9) 76 (20.4) 34 (26.2)
   Both parents 16 (2.4) 13 (2.2) 3 (4.4) 8 (2.2) 4 (3.1)
  MBA† 776±467 758±459 959±483 <0.001 647±426 949±468 <0.001
  RHI† 2.13±0.67 2.17±0.68 1.89±0.55 <0.001 2.23±0.70 2.05±0.63 0.005
  Fasting glucose (mmol/L)† 5.3±0.52 5.3±0.47 5.9±0.55 <0.001 5.1±0.39 5.4±0.37 <0.001
  Fasting insulin (µU/mL)‡ 9.2 (1.02) 8.9 (1.02) 13.1 (1.07) <0.001 8.0 (1.02) 10.3 (1.04) <0.001
  2- hour glucose (mmol/L)† 6.2±1.69 6.0±1.54 8.1±1.77 <0.001 5.4±1.13 6.3±1.0 <0.001
  HOMA- IR‡ 2.16 (1.02) 2.06 (1.02) 3.41 (1.07) <0.001 1.82 (1.03) 2.46 (1.04) <0.001
  HOMA- beta‡ 105 (1.02) 104 (1.02) 114 (1.07) 0.185 102 (1.02) 110 (1.04) 0.102
  HbA1c (mmol/mol)† 36.5±3.53 36.0±3.34 39.6±3.38 <0.001 35.4±3.19 37.2±3.13 <0.001
  HbA1c (%)† 5.5±0.32 5.4±0.29 5.8±0.32 <0.001 5.4±0.28 5.5±0.28 <0.001
Variables measured at follow- up (FF4)
  Fasting glucose (mmol/L)† 5.7±0.81§ 5.5±0.54 6.8±1.52 <0.001 5.3±0.40 6.0±0.58 <0.001
  Fasting insulin (µU/mL)‡ 10.3 (1.02)§ 9.9 (1.05)¶ 14.9 (1.17) <0.001 8.7 (1.05) 13.4 (1.12) <0.001
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  HOMA- IR‡ 2.53 (1.02)§§ 2.41 (1.05)¶ 4.54 (1.20)¶¶ <0.001 2.01 (1.07) 3.54 (1.12)*** <0.001
  HOMA- beta‡ 101 (1.02)§§ 102 (1.05)¶ 99 (1.20)¶¶ 0.862 100 (1.05) 109 (1.12)*** 0.117
  HbA1c (mmol/mol)† 37.1±4.81††† 36.4±3.67 42.8±8.2‡‡‡ <0.001 35.9±3.16 37.9±4.22 <0.001
  HbA1c (%)† 5.6±0.44††† 5.5±0.34 6.1±0.75‡‡‡ <0.001 5.4±0.29 5.6±0.39 <0.001
*For differences between groups: Kruskal- Wallis test for continuous variables; χ² test for categorical variables.
†Continuous variables are presented as arithmetic mean±SD.











HbA1c, hemoglobin A1c; HDL, high- density lipoprotein; HOMA- beta, homoeostasis model assessment of beta- cell function; HOMA- IR, 
homoeostasis model assessment of insulin resistance; MBA, mean baseline amplitude; RHI, reactive hyperemia index.
Table 1 Continued
Table 2 Association of baseline RHI and MBA with incident (pre)diabetes and incident type 2 diabetes
Model 1 Model 2
OR (95% CI) P value OR (95% CI) P value
RHI
  Incident T2D* vs no incident T2D† 0.64 (0.45 to 0.88) 0.009 0.69 (0.48 to 0.97) 0.043
  Incident (pre)diabetes‡ vs NGT§ 0.79 (0.63 to 0.97) 0.032 0.80 (0.63 to 1.02) 0.076
MBA
  Incident T2D* vs no incident T2D† 1.37 (1.04 to 1.80) 0.024 1.20 (0.89 to 1.61) 0.238
  Incident (pre)diabetes‡ vs NGT§ 1.83 (1.45 to 2.32) <0.001 1.62 (1.25 to 2.11) <0.001
ORs per 1 SD increased RHI or increased MBA estimated by multivariable logistic regression models.
Model 1 (basic model)=age, sex.
Model 2 (further risk factors)=model 1+waist circumference, height, triglycerides, total cholesterol/high- density lipoprotein, hypertension, 





MBA, mean baseline amplitude; NGT, normal glucose tolerance; RHI, reactive hyperemia index; T2D, type 2 diabetes.
did not influence baseline pulse amplitude (MBA) but 
significantly decreased reactive hyperemia assessed 
through PAT. Baseline pulse amplitude (MBA) changed 
significantly by infusion with the vasoconstrictor phen-
ylephrine, whereas reactive hyperemia did not change. 
Moreover, phenylephrine acts independently of NO.31 
This could indicate that MBA and RHI reflect different 
endothelium- related functions, which might relate to 
why MBA and RHI showed differing associations with 
incident (pre)diabetes and type 2 diabetes in the present 
study. As experimental data explaining the link between 
endothelial function and the continuum of dysglycemia 
are very limited, we can only speculate about potential 
mechanisms: in endothelial cells, reduced bioavailability 
of NO (less vasodilation, measured with RHI) contributes 
to insulin resistance.32 Moreover, the reduction of NO 
appears early in the development of insulin resistance and 
the anti- inflammatory effect of NO signaling is related to 
improvement of insulin resistance in multiple organs.33 
In the present study, persons with incident prediabetes 
were less insulin resistant compared with persons with 
incident type 2 diabetes, which might explain the lacking 
association of RHI with incident (pre)diabetes. Of note, 
lower RHI values were significantly associated with inci-
dent type 2 diabetes and with higher fasting insulin and 
HOMA- IR levels at follow- up in participants with initial 
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Figure 2 Association of baseline RHI and MBA with follow- up insulin and glucose parameters. Standardized z- score β 
estimates with 95% CIs for the association of insulin and glucose parameters per 1 SD increase in RHI and MBA estimated by 
multivariable linear regression models (only participants with NGT at baseline). Results are from model 2, adjusted for age, sex, 
the baseline value (at F4) of the outcome variables, waist circumference, height, triglycerides, total cholesterol/high- density 
lipoprotein, hypertension, smoking status, alcohol intake, physical activity, years of education, high- sensitivity C reactive 
protein and parental history of diabetes. HbA1c, hemoglobin A1c; HOMA- beta, homeostasis model assessment of beta- 
cell function; HOMA- IR, homeostasis model assessment of insulin resistance; MBA, mean baseline amplitude; NGT, normal 
glucose tolerance; RHI, reactive hyperemia index.
normoglycemia. Furthermore, adjustments for fasting 
insulin as well as HOMA- IR attenuated the association 
between RHI and incident type 2 diabetes, suggesting 
a possible mediating role of insulin resistance. This 
further underlines the concept that RHI reflects NO 
reduction, which promotes insulin resistance leading 
over time to manifested diabetes. An intervention study 
supports this concept as they proposed that changes in 
HOMA- IR through exercise training were independently 
correlated with changes in RHI in patients with obesity.34 
Along these lines, experimental data in mouse models 
of obesity demonstrated that reduced glucose uptake 
within the skeletal muscle is caused by impaired insulin 
signaling in endothelial cells due to reduced insulin- 
induced endothelial NO (vasodilator) synthase phos-
phorylation and insulin receptor substrate 2 expression. 
This leads to decreased insulin delivery to the skeletal 
muscle, reducing the uptake of glucose into skeletal 
muscle35 and in the long run possibly to the manifestation 
of type 2 diabetes. The lack of association between MBA 
and HOMA- IR as well as fasting insulin could potentially 
explain the missing link to type 2 diabetes development.
The MBA reflects the pulse waves, that is, pressure 
changes, which result from volume differences due to 
changes in the arteriolar volume of the finger.27 Higher 
pressure and volume changes could reflect increased 
blood flow. This is based on the observation that after 
the release of the blood pressure cuff the pulse ampli-
tude increases compared with baseline values9 because 
the release of the cuff provokes increased blood flow. 
Without this external obstruction an increased blood 
flow might also be necessary in other conditions which 
obstruct the vessel for a longer time in order to still trans-
port enough oxygen to demanding structures. Molecules, 
such as leukocytes binding to the vessel wall, decrease the 
space of the bloodstream and lead to obstruction.5 As the 
endothelium’s function is to regulate blood flow13 and 
blood fluidity,1 baseline pulse amplitude (MBA) might be 
an important indicator of microvessel function in addi-
tion to microvessel structure.36 Higher MBA values could 
reflect the increased blood flow and therefore severity of 
the vessel obstruction.
Previous studies have suggested that higher glucose 
levels impair endothelial function,37 38 possibly because 
elevated glucose levels increase platelet aggregation, 
inhibit fibrinolysis39 and lead to coagulation indepen-
dent of insulin levels in healthy subjects.40 The under-
lying mechanisms include the transport of glucose into 
endothelial cells by diffusion independently of insulin. 
If endothelial cells in vitro are exposed to high glucose, 
they increase the production of fibronectin and proco-
agulant proteins and decrease fibrinolytic potential,41 all 
leading to higher obstruction within the vessel and there-
fore possibly increased MBA. The longitudinal results 
of the present study suggest these observations vice 
versa. Especially in persons with initial NGT, decreased 
microcirculation as reflected by increased MBA may 
also lead to increased glucose levels over time. Further-
more, elevated fasting glucose concentrations at baseline 
partly explained the strong association between MBA 
and incident (pre)diabetes suggesting a potential medi-
ating role of fasting glucose. As other longitudinal and 
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experimental studies addressing this potential mecha-
nism are largely lacking, further research is necessary in 
this respect.
We further demonstrated that in participants with 
prediabetes at baseline, baseline RHI and MBA were not 
associated with follow- up values of the continuous traits. 
As we found multiple associations in persons with NGT at 
baseline, this might reflect that RHI and MBA are both 
mainly related to the early impairment of glucose metab-
olism and early stages of insulin resistance.
strengths and limitations
A major strength of this project constitutes the 
population- based longitudinal design with availability 
of standardized covariates enabling inclusion of a large 
number of confounders into the models. Furthermore, a 
standardized OGTT was performed to determine previ-
ously unknown diabetes and prediabetes cases. Measure-
ments of endothelial function were performed in a 
highly standardized manner using PAT technology and 
only measurements with good quality were included in 
the present analyses. Limitations of this project include 
the relatively low number of participants, who developed 
incident type 2 diabetes during the follow- up period. 
Furthermore, as the study only included predominantly 
white Europeans between the age of 52 and 71 years, 
the results cannot be generalized to younger adults or 
other ethnicities. Furthermore, the PAT measurement 
represents only an indirect measurement of endothelial 
function.
ConClusIon
The present analysis is the first to present longitudinal 
data on the association of PAT- derived microvascular 
endothelial dysfunction with type 2 diabetes. We observed 
an inverse association of the microvascular endothelial 
function parameter RHI, which reflects reactive vasodi-
lation, with the development of incident type 2 diabetes 
and a positive association of MBA reflecting blood flow 
with incident (pre)diabetes. Thus, microvascular endo-
thelial dysfunction seems to be involved in the devel-
opment of early derangements in glucose and insulin 
metabolism and may thereby trigger the development of 
prediabetes and type 2 diabetes.
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